⚠ Evidence warning: Clinical trials or other evidence do not support the claim that cat's claw benefits inflammatory bowel disease, psoriasis, asthma, atherosclerosis and post-viral fatigue, spares the gut microbiome, and allows steroid or biologic dose reduction. This page keeps it as a report of what people, websites or other media say.

Cat's Claw Anti-Inflammatory (NF-kB & Tumor Necrosis Factor-alpha)

Anti Inflammatory — scientific infographic poster

The anti-inflammatory action of Cat's Claw is one of the cleanest mechanism-to-clinical-effect stories in plant medicine. The active fraction (a combination of pentacyclic oxindole alkaloids (POA), quinovic acid glycosides, and triterpenoids) is described as blocking the activation of NF-kB; in a 2000 study in mouse macrophage cells in a dish, a cat's claw water extract suppressed tumor necrosis factor-alpha production by approximately 65–85%. The downstream consequence is suppression of tumor necrosis factor-alpha, interleukin-1 (IL-1), interleukin-6 (IL-6), cyclooxygenase-2 (COX-2), and matrix metalloproteinases — the entire inflammatory cascade dampened simultaneously rather than blocked at any single effector. Sandoval-Chacon et al. reported in 1998 that cat's claw blocked NF-kB activation in cells in a dish and reduced indomethacin-induced inflammation of the small intestine (enteritis) in rats. The mechanism explains why Cat's Claw produces parallel effects in conditions as different as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease (IBD), and chronic neuroinflammatory states — all share NF-kB-driven inflammatory loops as a common pathway.


Table of Contents

  1. What NF-kB Is and Why It Matters
  2. The Sandoval-Chacon 1998 NF-kB Paper
  3. Tumor Necrosis Factor-alpha Reduction In Vitro and In Vivo
  4. Cat's Claw and Inflammatory Bowel Disease: Reported Use
  5. Cat's Claw vs Sulfasalazine
  6. Cat's Claw vs Nonsteroidal Anti-Inflammatory Drugs and Cyclooxygenase-2 Inhibitors
  7. Cat's Claw vs Corticosteroids
  8. Cat's Claw vs Tumor Necrosis Factor-alpha Inhibitor Biologics
  9. Other NF-kB-Driven Inflammatory Conditions
  10. Dosing, Standardization, and Form Selection
  11. What Rheumatology Reviewers Concluded in 2026
  12. Key Research Papers
  13. Connections
  14. Featured Videos

What NF-kB Is and Why It Matters

Nuclear factor kappa-B (NF-kB) is a family of transcription factors central to the regulation of inflammation, immune response, cell proliferation, and cell survival. In its inactive state, NF-kB exists as a dimer (most commonly the p50/p65 heterodimer) sequestered in the cytoplasm by its inhibitor protein IkB-alpha. The IkB-alpha "covers" the nuclear localization signal of NF-kB, preventing it from entering the nucleus to bind DNA.

Activating signals reach the cell through a wide variety of receptors:

All of these signals converge on activation of the IkB kinase (IKK) complex (IKK-alpha, IKK-beta, and NF-kB essential modulator (NEMO)), which phosphorylates IkB-alpha. Phosphorylated IkB-alpha is rapidly ubiquitinated and degraded by the proteasome, releasing NF-kB to translocate into the nucleus, where it binds to NF-kB response elements in the promoter regions of target genes and drives their transcription.

The target genes activated by NF-kB read like a catalog of inflammation:

The clinical relevance: persistent NF-kB activation is the molecular signature of essentially every chronic inflammatory and autoimmune disease — rheumatoid arthritis, inflammatory bowel disease, psoriasis, atherosclerosis, asthma, neuroinflammation, and most cancers. Targeting NF-kB therapeutically is correspondingly one of the most attractive but technically difficult goals in pharmacology, because NF-kB is also required for normal immune defense against infection. Complete NF-kB blockade is incompatible with life. Therapeutic NF-kB modulation needs to be partial and selective — which is what Cat's Claw extracts are proposed to produce.

Back to Table of Contents

The Sandoval-Chacon 1998 NF-kB Paper

The Sandoval-Chacon, Thompson, Zhang et al. paper published in Alimentary Pharmacology and Therapeutics in 1998 is the foundational mechanistic study establishing Cat's Claw as an NF-kB inhibitor. The work combined cells in a dish with a rat model. It was not a human study, and it included no comparison with any drug.

Design. In the cell tests, two cell lines — RAW 264.7 mouse macrophages and HT29 epithelial cells — were exposed to the oxidant peroxynitrite, and the activation of NF-kB was measured in RAW 264.7 cells. In the animal part, chronic intestinal inflammation was induced in rats with indomethacin (7.5 mg/kg), and cat's claw was given by mouth in the drinking water (5 mg/mL). The result was inflammation of the small intestine (indomethacin-enteritis), not of the colon.

Findings.

What the authors concluded. The authors concluded that cat's claw protects cells against oxidative stress and negated the activation of NF-kB, and that their studies provide mechanistic evidence for the widely held belief that cat's claw is an effective anti-inflammatory agent. One proposed explanation for how it blocks NF-kB is direct interference with the IKK-IkB-NF-kB signaling axis, possibly through inhibition of IKK activity or through stabilization of IkB-alpha; the paper's abstract does not test this.

The paper became the foundational reference for the next two decades of Cat's Claw inflammation research. Every subsequent study examining Cat's Claw in inflammatory disease has built on the NF-kB mechanism documented here.

Back to Table of Contents

Tumor Necrosis Factor-alpha Reduction In Vitro and In Vivo

Tumor necrosis factor-alpha is one of the most studied pro-inflammatory cytokines because it sits at the apex of many inflammatory disease cascades. Originally identified for its ability to induce tumor necrosis (hence the name), it is now recognized as the central driver of inflammation in rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis — conditions whose modern blockbuster treatment is the class of tumor necrosis factor-alpha inhibitor biologic drugs (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).

Cat's Claw's tumor necrosis factor-alpha-reducing activity has been documented in three complementary lines of evidence:

The tumor necrosis factor-alpha-reducing effect is mechanistically downstream of the NF-kB inhibition. NF-kB drives transcription of the tumor necrosis factor-alpha gene, so reducing NF-kB activity reduces tumor necrosis factor-alpha production proportionally. Tumor necrosis factor-alpha has multiple input drivers, only some of which are NF-kB-mediated. The tumor necrosis factor-alpha figures above come from mouse cells in a dish.

Back to Table of Contents

Cat's Claw and Inflammatory Bowel Disease: Reported Use

Cat's claw (uña de gato) is used in traditional Peruvian medicine for a wide range of health problems, particularly digestive complaints and arthritis, as the 1998 Sandoval-Chacon paper notes. Practitioners also use it in inflammatory bowel disease (Crohn's disease and ulcerative colitis), usually alongside a person's existing inflammatory bowel disease medicines, and people who take it describe easing of symptoms such as abdominal pain, stool frequency and blood in stool.

The published research behind this use is the cell and rat work described above: the 1998 study induced inflammation of the small intestine with indomethacin, and the 2002 study used an indomethacin gastritis model. No published trial of cat's claw in people with inflammatory bowel disease was found in PubMed. Larger randomized controlled trials have not been done — partly because Cat's Claw cannot be patented as a drug and the financial incentive for industry-funded trials is absent.

Practitioners describe Cat's Claw as an add-on for people whose disease stays active despite conventional therapy (mesalamine, azathioprine, biologics), not as a substitute for established inflammatory bowel disease therapy. Supporters of pentacyclic-chemotype products hold that only POA-standardized extracts count; the 2002 Sandoval study found that the alkaloids did not influence the anti-inflammatory activity (see Dosing, Standardization, and Form Selection).

Back to Table of Contents

Cat's Claw vs Sulfasalazine

Sulfasalazine is the prototypical first-generation drug for both inflammatory bowel disease (specifically ulcerative colitis) and rheumatoid arthritis. It is a sulfonamide-salicylate conjugate that is cleaved by colonic bacteria into two active metabolites:

Comparison with Cat's Claw on multiple dimensions:

In ulcerative colitis or rheumatoid arthritis, sulfasalazine has the larger evidence base. Practitioners describe Cat's Claw as an option for people who cannot tolerate sulfasalazine (sulfa allergy, hematologic effects, hepatic effects, persistent gastrointestinal intolerance) or who want an additional anti-inflammatory layer on top of existing therapy.

Back to Table of Contents

Cat's Claw vs Nonsteroidal Anti-Inflammatory Drugs and Cyclooxygenase-2 Inhibitors

Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, indomethacin, meloxicam) and cyclooxygenase-2-selective inhibitors (celecoxib, rofecoxib historically, etoricoxib in some markets) work by inhibiting cyclooxygenase enzymes that convert arachidonic acid to inflammatory prostaglandins (prostaglandin E2 (PGE2) in particular). The COX inhibition reduces pain, fever, and acute inflammation but does nothing about the upstream NF-kB signaling, the cytokine cascade, or the matrix-destroying enzymes that drive chronic inflammatory disease progression.

Mechanism comparison:

Clinical comparison:

The adjunctive approach practitioners describe: for people with chronic inflammatory pain who take ongoing analgesic therapy, Cat's Claw (NF-kB modulation, slow onset, broad anti-inflammatory) plus as-needed low-dose nonsteroidal anti-inflammatory drugs for breakthrough symptoms, with the aim of lower nonsteroidal anti-inflammatory drug exposure and less of its gastrointestinal / renal / cardiovascular risk.

Back to Table of Contents

Cat's Claw vs Corticosteroids

Corticosteroids (prednisone, prednisolone, methylprednisolone, dexamethasone, hydrocortisone) are the most powerful broad-spectrum anti-inflammatory drugs in clinical use. They work through binding to the cytoplasmic glucocorticoid receptor and translocating into the nucleus, where they directly transrepress NF-kB (and AP-1) target genes at the transcriptional level — a mechanism that overlaps substantially with the Cat's Claw NF-kB inhibition mechanism, except corticosteroids work much more powerfully.

The clinical use case for corticosteroids in chronic inflammatory disease is generally as bridge therapy or as flare control, not as long-term maintenance, because of the side-effect profile:

Cat's Claw has none of these adverse effects at conventional doses. The trade-off is that Cat's Claw is also dramatically less powerful — a 5 mg/day dose of prednisone produces broad anti-inflammatory effects that no botanical preparation can match.

In chronic inflammatory disease, where low-dose maintenance corticosteroids are used for symptom control on top of disease-modifying antirheumatic drug (DMARD) therapy (a common scenario in long-standing rheumatoid arthritis), practitioners describe adding Cat's Claw as an adjunct with the goal of potentially permitting steroid dose reduction. The Mur trial added the extract or placebo to sulfasalazine or hydroxychloroquine treatment. Chronic steroid use suppresses the adrenal axis (see the list above), which is why steroid doses are reduced by slow tapering, with disease activity markers and adrenal axis function tracked along the way.

Back to Table of Contents

Cat's Claw vs Tumor Necrosis Factor-alpha Inhibitor Biologics

Tumor necrosis factor-alpha inhibitor biologics (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) are large-molecule drugs that directly bind and neutralize circulating tumor necrosis factor-alpha or block the TNFR1 receptor. They are highly effective in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and psoriasis. They are also expensive ($20,000–$60,000/year retail in the US), require subcutaneous or intravenous injection, and carry serious risks including reactivation of latent tuberculosis, opportunistic fungal infections, hepatitis B reactivation, and rare but serious heart-failure exacerbation and lymphoma.

Mechanism comparison:

The magnitudes are not comparable. A patient on adalimumab effectively has tumor necrosis factor-alpha neutralized as a clinically relevant cytokine. A patient on Cat's Claw has tumor necrosis factor-alpha output modestly reduced.

How practitioners position it:

Back to Table of Contents

Other NF-kB-Driven Inflammatory Conditions

Because NF-kB is the common transcriptional engine of essentially every chronic inflammatory disease, the Cat's Claw mechanism translates — with varying levels of clinical evidence — to multiple non-arthritis indications:

Back to Table of Contents

Dosing, Standardization, and Form Selection

Supporters of pentacyclic-chemotype products apply the same dosing and product-selection logic to anti-inflammatory use as to immune modulation: in their view chemotype certification matters more than dose, and a POA-standardized extract at moderate dose outperforms a non-standardized bulk product at high dose.

The research group that first studied cat's claw for inflammation reported a different result in 2002. In the Sandoval study, the presence of oxindole or pentacyclic alkaloids did not influence the anti-inflammatory and antioxidant activity of cat's claw. Extract fractions without alkaloids lowered LPS-induced tumor necrosis factor-alpha and nitrite production in RAW 264.7 mouse cells at a concentration range comparable to the whole plant. The total oxindole and pentacyclic alkaloid content of Uncaria tomentosa was 35-fold greater than that of the related species Uncaria guianensis, yet U. guianensis was the more potent of the two.

The dosing landmarks used in practice and in trials:

Time to clinical effect for anti-inflammatory indications is typically 4–12 weeks. Because its effects build over weeks, Cat's Claw is used as a maintenance and adjunctive therapy rather than for acute inflammatory flares, which are treated with conventional therapy (steroids, nonsteroidal anti-inflammatory drugs, biologics depending on disease).

For the disease-specific clinical evidence in rheumatoid arthritis, see the rheumatoid arthritis deep-dive. For the immune-modulation framework underlying the broader effects, see the immune modulation deep-dive. For the application to chronic Lyme disease and tick-borne co-infections (where NF-kB modulation of neuroinflammation is a key adjunctive role), see the Lyme-disease deep-dive.

Back to Table of Contents

What Rheumatology Reviewers Concluded in 2026

In 2026 a committee of the German Society for Rheumatology and Clinical Immunology (DGRh) published its review of 13 more herbal preparations frequently used in rheumatology, mostly as self-medication; cat's claw (Uncaria tomentosa) was one of them. For all the plant substances investigated, the committee found reports of anti-inflammatory or immune effects in cells and/or in animal models, but “the evidence for a clinically relevant benefit is very limited”. It concluded that none of the investigated preparations can be recommended for use in inflammatory joint diseases.

Back to Table of Contents

Key Research Papers

  1. Sandoval-Chacón M, Thompson JH, Zhang XJ, et al. (1998). Antiinflammatory actions of cat's claw: the role of NF-kappaB. Alimentary Pharmacology & Therapeutics 12(12): 1279–1289. — PubMed PMID: 9882039
  2. Sandoval M, Charbonnet RM, Okuhama NN, et al. (2000). Cat's claw inhibits TNF-alpha production and scavenges free radicals: role in cytoprotection. Free Radical Biology and Medicine 29(1): 71–78. — PubMed PMID: 10962207
  3. Sandoval M, Okuhama NN, Zhang XJ, et al. (2002). Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 9(4): 325–337. — PubMed PMID: 12120814
  4. Aguilar JL, Rojas P, Marcelo A, et al. (2002). Anti-inflammatory activity of two different extracts of Uncaria tomentosa (Rubiaceae). Journal of Ethnopharmacology 81(2): 271–276. — PubMed PMID: 12065162
  5. Allen-Hall L, Cano P, Arnason JT, et al. (2007). Treatment of THP-1 cells with Uncaria tomentosa extracts differentially regulates the expression of IL-1beta and TNF-alpha. Journal of Ethnopharmacology 109(2): 312–317. — PubMed PMID: 16959454
  6. Åkesson C, Lindgren H, Pero RW, et al. (2003). An extract of Uncaria tomentosa inhibiting cell division and NF-kappaB activity without inducing cell death. International Immunopharmacology 3(13–14): 1889–1900. — PubMed PMID: 14636838
  7. Mur E, Hartig F, Eibl G, Schirmer M (2002). Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. Journal of Rheumatology 29(4): 678–681. — PubMed PMID: 11950006
  8. Piscoya J, Rodriguez Z, Bustamante SA, et al. (2001). Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflammation Research 50(9): 442–448. — PubMed PMID: 11603848
  9. Karin M, Greten FR (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 5(10): 749–759. — PubMed PMID: 16175180
  10. Lawrence T (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspectives in Biology 1(6): a001651. — PubMed PMID: 20457564
  11. Snow AD, Castillo GM, Nguyen BP, et al. (2019). The Amazon rain forest plant Uncaria tomentosa (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. Scientific Reports 9: 561. — PubMed PMID: 30728442
  12. Bhardwaj A, Aggarwal BB (2003). Receptor-mediated choreography of life and death. Journal of Clinical Immunology 23(5): 317–332. — PubMed PMID: 14601641 — a review of tumor necrosis factor-alpha and NF-kB signaling.
  13. Portalatin G, Shettigar S, Carrion-Rodriguez A, Medikayala S, Herlitz L, Sandy D, Gebreselassie SK, Bobart SA (2022). Ketogenic-Diet Shake Containing Uncaria tomentosa-Associated Acute Interstitial Nephritis. Case Reports in Nephrology and Dialysis 12(3): 219–225. — PubMed PMID: 36465572
  14. Keyßer G, Sander O, Frohne I, Pfeil A, Michalsen A, Schultz O, Reuß-Borst M, Seifert O; DGRh-Kommission für Komplementäre Heilverfahren und Ernährung (2026). Recommendations of the German Society for Rheumatology committee for complementary treatment and nutrition on phytotherapy: Supplement on the use of selected phytotherapeutic agents and herbal preparations in rheumatology: extension to include 13 medicinal plants [article in German]. Zeitschrift für Rheumatologie 85(8): 655–672. — PubMed PMID: 42448806

PubMed Topic Searches

  1. PubMed: Uncaria tomentosa NF-kB
  2. PubMed: Uncaria tomentosa TNF-alpha
  3. PubMed: Cat's Claw in inflammatory bowel disease
  4. PubMed: Cat's Claw vs sulfasalazine
  5. PubMed: Plant-derived NF-kB inhibitors

Back to Table of Contents

Connections

Back to Table of Contents